Grifols, S.A. (NASDAQ:GRFS) Shares Sold by Point72 Asset Management L.P.

Point72 Asset Management L.P. lessened its holdings in Grifols, S.A. (NASDAQ:GRFS) by 22.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 465,768 shares of the biotechnology company’s stock after selling 131,077 shares during the quarter. Point72 Asset Management L.P.’s holdings in Grifols were worth $4,136,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in shares of Grifols by 49.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 1,135 shares during the last quarter. Signaturefd LLC lifted its position in Grifols by 66.2% during the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 2,153 shares during the period. AQR Capital Management LLC purchased a new stake in Grifols in the second quarter valued at $89,000. HighTower Advisors LLC grew its position in Grifols by 12.5% during the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 1,546 shares during the period. Finally, Cetera Advisors LLC acquired a new stake in Grifols during the 1st quarter worth about $147,000.

Analysts Set New Price Targets

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Price Performance

NASDAQ:GRFS opened at $7.30 on Monday. The company has a 50 day moving average price of $8.60 and a 200-day moving average price of $8.09. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $12.15. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.